BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stephenson J, Richards DA, Wolpin BM, Becerra C, Hamm JT, Messersmith WA, Devens S, Cushing J, Goddard J, Schmalbach T, Fuchs CS. The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer. JCO 2011;29:4114-4114. [DOI: 10.1200/jco.2011.29.15_suppl.4114] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Lai E, Puzzoni M, Ziranu P, Pretta A, Impera V, Mariani S, Liscia N, Soro P, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Pireddu A, Demurtas L, Pusceddu V, Camera S, Sclafani F, Scartozzi M. New therapeutic targets in pancreatic cancer. Cancer Treat Rev 2019;81:101926. [PMID: 31739115 DOI: 10.1016/j.ctrv.2019.101926] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
2 Kanat O, Ertas H. Shattering the castle walls: Anti-stromal therapy for pancreatic cancer. World J Gastrointest Oncol 2018; 10(8): 202-210 [PMID: 30147846 DOI: 10.4251/wjgo.v10.i8.202] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
3 Perrot CY, Javelaud D, Mauviel A. Overlapping activities of TGF-β and Hedgehog signaling in cancer: therapeutic targets for cancer treatment. Pharmacol Ther. 2013;137:183-199. [PMID: 23063491 DOI: 10.1016/j.pharmthera.2012.10.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
4 Li F, Zhao C, Wang L. Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer 2014;134:1257-69. [PMID: 23649791 DOI: 10.1002/ijc.28261] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 8.7] [Reference Citation Analysis]